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Pancreatic Pathology
ROBERT T. JENSEN, M.D.
This section, entitled "Pancreatic Pathology," includes a spectrum of topics on
normal and abnormal pancreatic tissue. Specifically, two presentations deal with
characterization of cholecystokinin (CCK) receptors on normal tissues. Wank has
recently reported the purification, cloning, and expression of the CCKA receptor
from rat pancreas, and the article by Miller deals with the biochemical characteriza-
tion ofthe CCKA receptor, primarily in gallbladder and pancreatic membranes. The
article by Logsdon et al. deals with the effects ofCCK on activating immediate early
gene expression in normal pancreas, and the otherwith pancreatic cancer, including
recent results ofstudies in animal models ofpancreatic carcinoma (by Longnecker et
al.) and the relationship between pancreatic cancer and diabetes mellitus (by Pour
and colleagues).
Before considering a few concluding remarks on each paper and points that arose
in the questions, because a significant proportion of the papers deal with CCK
receptors, Table 1 is included, which summarizes a number of points about the
classification of CCK receptors that should be kept in mind in assessing these
presentations. CCK and gastrin share the same COOH terminal pentapeptide, and
they cause changes in biologic activity or interaction with receptors in binding
experiments examining different relative affinities with a number oftissues [1,2]. It is
generally agreed, from numerous pharmacological studies, that there are at least two
classes of CCK/gastrin receptors [2,3]; one is a CCKA subtype, which interacts with
high affinity onlywith CCK/gastrin analogs sulfated in the seventh position from the
COOH terminus. Because gastrin, even when sulfated (gastrin-17-II) is sulfated in
the sixth position from the COOH terminus, this receptor has a low affinity for all
forms of gastrin [3,4]. This receptor is thought to be the physiologically important
receptor mediating the action of CCK on gallbladder contraction, pancreatic secre-
tion, and satiety [1,2,5,6]. Both selective agonists and antagonists now exist for the
CCKA subtype; this subtype is found on a number ofother tissues, as shown in Table
1, and in the central nervous system (CNS) is present in only a few specific locations,
such as the area postrema, certain intrapenduncular nuclei, and the nucleus tractus
solitarius [6,7]. Extensive studies have demonstrated that occupation ofthis receptor
causes activation ofphospholipase C with changes in cellular calcium and phospho-
inositides [2,8]. It is unclear at present whether one subtype, a CCKB/gastrin, or two
subtypes, a CCKB and a gastrin receptor, or more, mediate the high-affinity interac-
tions with gastrin and non-sulfated CCKanalogs seen in the CNS andvarious tissues
(Table 1) [2,3]. The CCKB receptor was characterized primarily in the CNS by
binding studies, where it iswidely distributed, especially in the cerebral cortex, and is
distinguished by having a high affinity for CCK, gastrin, and various antagonists
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TABLE 1
Classification ofReceptors for Cholecystokinin/Gastrin-Related Peptides
CCK Receptors
CCKA CCKB ? Gastrin
Agonists:
General CCK-8>> Gastrin (1,000x) CCK-8 > Gastrin (3-10x) CCK = Gastrin
Selective A71387 SNF8702
Gastrin
Antagonists L-364,718, Lorglumide L-365,260, PD134,308
Location Pancreas Cerebral cortex Parietal
Gallbladder GI smooth muscle GI smooth muscle
Anterior pituitary Pancreas
Gastric smooth muscle Cell lines AR42J and human
LES inhibit neurons small-cell cancer
Area postrema-CNS
Pyloric sphincter
Cell lines-AR42J
Cellular Mediator IP3 IP3
C2+ ?C2+ Ca2 CA2
Modified from [1,3]
(Table 1) [6,7,9]. At present, the cellular basis of action of this receptor in the
cerebral cortex is unclear, although a pharmacologically similar receptor exists on
human small-cell lungcancercells and occupationofthis receptor activates phospho-
lipase C (refer to Table 1) [10,11]. The action of gastrin was originally described on
gastric acid secretion [1]; subsequent studies demonstrated that parietal cells pos-
sessed a receptor with equal high affinity for CCK and gastrin, and later studies
demonstrated that the cellular basis of action of these peptides was by activating
phospholipase C [12,13]. A particularly important point to remember is that CCK or
its COOH terminal octapeptide (CCK-8) has high affinity for all classes of CCK
receptors and, therefore, any given physiological or pharmacologic action by these
peptides described in the various papers can be through any or all ofthese receptors
[2,4,14].
The recent report by Wank and colleagues represents a particularly important
advance: this study reports for the first time the cloning of the CCKA receptor
through which CCK alters pancreatic acinar cellular function. That study [5],
coupled with the recent cloning of the gastrin receptor from dog parietal cells [15],
unequivocally establishes that the CCKA and gastrin receptors are distinct receptors.
What remains not as yet established is whether there is a distinct CCKB receptor or
how many additional subclasses of CCK receptors mediate the actions of CCK/
gastrin peptides. Within the next year, it is likely that this question will be answered.
It is also likely, with the availability ofcells transfected with these receptors, that the
pharmaceutical companies will rapidly develop increasingly selective compounds,
which should prove useful in exploring the actions of CCK in mediating various
physiological processes. The cloning of this family of receptors not only allows the
cell biology of the CCK receptor to be studied in detail, it also opens the possibility
that disease states may be found with alterations in this receptor, such as in some
neoplasias, obesity, or possibly gastric secretory or intestinal motility disorders.
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The article by Miller summarizes his extensive studies, usingvarious cross-linking
techniques to characterize CCK receptors on a number of tissues as well as recent
research on possible regulation of the CCK receptor by phosphorylation. These
studies have provided important findings, which can now be confirmed and extended
more easily because of the recent cloning of the CCKA receptor. For example,
cross-linking studies suggest that gallbladder and pancreatic CCKA receptors are
probably the same, even though some previous pharmacological studies [16], usually
performed in different species, have raised the possibility theymaybe pharmacologi-
cally distinct. This question will presumably be unequivocally answered in the next
year with the recent cloning of the CCKA receptor. Another important area high-
lighted by this study is that CCK and a number of secretagogues, which act via a
similar intracellular cascade to CCK (i.e., carbachol, TPA) that cause activation of
phospholipase C, mobilization ofcellular calcium, or protein kinase C activation, can
cause specificphosphorylation ofthe CCKreceptor, suggestingthat protein kinase C
maybe involved aswell as a kinase analogous to the 3-adrenergic receptor kinase. A
number of studies have shown that CCK can induce desensitization [17,18] and
whether this phosphorylation relates to this phenomenon or contributes to the
unusual biphasic dose-response curve caused by CCK with enzyme secretion will
probably be answered in the future by extensions of these researches. Furthermore,
the availability ofpossible antibodiesgenerated against specific CCKA receptor areas
will likely allow these studiesofthe regulation ofthe CCKA receptorbyphosphoryla-
tion and phosphatases to be investigated in detail more easily in the future.
The article by Logsdon et al. presents their recent important studies involving
non-secretory effects ofCCK. It is known that long-term CCK administration causes
pancreatic growth effects and adaptative changes in the pancreatic acinar cell with
changes in digestive enzyme genes. These researches clearly demonstrate that CCK
in normal pancreas has effects on activation of the immediate early genes c-fos,
c-myc, and c-Jun, and that probably cAMP, protein kinase C, and calcium-sensitive
response elements are important in mediating these effects. This paper has impor-
tant implications for the action, not only of CCK/gastrin-related peptides in the
pancreas, but also in other tissues. CCK-related peptides are known to affect the
growth of a number of normal tissues as well as to affect growth of a number of
tumors [19-21]. Various different experimental protocols demonstrate that CCKcan
promote the development of pancreatic neoplasms such as those in animals treated
long-term with trypsin inhibitors, which result in elevated CCK levels [22,23].
Furthermore, administration ofCCKanalogspromote azaserine-induced carcinogen-
esis [24,25]. These studies, as well as the results reported by Logsdon et al., clearly
emphasize the importance of understanding the molecular basis for long-term
cellular changes induced by CCK in the pancreas and other tissues. Other reports
suggest that similar studies will be equally important with respect to gastrin. Recent
researches showthatchronichypergastrinemia induceshyperplasiaofenterochromaf-
fin-like cells (ECL cells) in the gastric mucosa and, in some cases, malignant
carcinoid tumors develop [26,27]. Because of the widespread increased long-term
use of potent gastric anti-secretory agents such as the gastric H+/K+-ATPase
inhibitor omeprazole, which can cause achlorhydric and chronic hypergastrinemia
[26,27], the molecular basis for the long-term growth effects of gastrin on the
stomach have important clinical implications.
The article by Longnecker et al. discusses recent results in animal models of
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pancreatic cancer, reviews the differences that are being found with these diverse
models, and also points out the difficulty in establishing the cell of origin of the
various histologic types ofpancreatic tumors found inthese models. It is importantto
remember that pancreatic cancer is the fifth most common cause of cancer death,
with an average survival of only three months. Therefore, current therapies are
clearly unsatisfactory. One ofthe main difficulties in studying the biology ofpancre-
atic cancer is the relative inaccessibility of tissue until late in the course of the
disease. These tumors almost all present late in their course, and, because of the
inaccessibility of the gland, detection of asymptomatic early lesions almost never
occurs. Therefore, in contrast to such tumors as gastric or colon adenocarcinoma,
wherevarious early stages ofthe tumorcan be easily approached endoscopically, this
procedure is not possible in pancreatic cancer and thus, onlyby developing adequate
animal models ofthis tumor, will unique features ofits cellbiology and pathogenesis
be resolved. The development of appropriate animal models of this tumor would
probably prove to be extremely helpful in better understanding the cellular origin of
these tumors and studying their cellbiology.
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